Benchmarking syngeneic tumor models to explore immunopathogenesis and anti-PD1 mechanism of actiondoi:10.1016/S0959-8049(20)31237-5A.X. AnY. JinB. MaoD. OuyangH. LiEuropean Journal of Cancer
PD-(L)1 blockade and anti-CTLA-4 therapy operate in different phases of the immune response, which explains the basis of their combined mechanism of action. PD-1 is mostly expressed on late effector phase CD4+ helper T cells and CD8+ cytotoxic T cells in peripheral tissues. Anti-PD-1 tr...
Although the PD-L1 molecule is involved in the mechanism of action of anti-PD-1 therapies, other aspects of adaptive immunity, namely T cells, may be more useful in predicting response8. T cells can be classified according to their activation and differentiation status, which capture the activi...
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opin. Drug Deliv. 18, 187–203 (2021). Article CAS PubMed Google Scholar Wang, F. H. et al. Efficacy, safety, and correlative biomarkers of toripalimab ...
S. Clinical blockade of PD1 and LAG3 [mdash] potential mechanisms of action. Nat. Rev. Immunol. 15, 45–56 (2015). Article CAS Google Scholar Kleinovink, J. W. et al. PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. Oncoimmunology 6, e1294299 (2017). ...
+hematopoietic stem cells into nonlethally irradiated 3–4-week-old mice. After both PDXs and melanoma cell xenografts reached ~ 150–200 mm3, animals were treated with humanized anti-PD-1 antibody or anti-CTLA-4 and evaluated for tumor growth, survival, and potential mechanism of action....
In fact, in 2 trials the incorporation of avelumab and atezolizumab (anti-PD-L1) failed to demonstrate benefit in PFS and OS [1], [5]. Moreover, a different mechanism of action between anti-PD1 and anti-PD-L1 yet demonstrated in other solid tumors could justify the differential ...
The production of extracellular adenosine in solid tumors was recently identified as a major immunosuppressive pathway, targeting this pathway would enhance the therapeutic activity of anti-PD1 mAbs. In this study, we evaluated the anti-tumor activity and mechanism of action of caffeine and anti-PD1...
Targeting co-stimulatory molecules with agonistic antibodies: mechanism of action and characteristics The main strategy for utilizing these molecules in cancer immunotherapy is developing agonistic antibodies or agonists. Different from ICIs blocking receptor/ligand interactions and TAA mAbs inducing ADCC/CDC,...
In recent years, with greater understanding of the mechanism of tumor immune escape and the tumor microenvironment, immune-checkpoint inhibitor-based therapies have shown satisfactory clinical efficacy in a variety of tumors. Immunotherapy plays an important role in the treatment of malignant tumors, and...